Grace Therapeutics, Inc.
GRCE
$2.27
-$0.03-1.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.18M | -2.31M | -939.00K | -3.36M | 636.00K |
| Total Depreciation and Amortization | 2.00K | 3.00K | 0.00 | 2.00K | 2.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.52M | 148.00K | -1.22M | 789.00K | -3.53M |
| Change in Net Operating Assets | 999.00K | -67.00K | -983.00K | 770.00K | -66.00K |
| Cash from Operations | -1.70M | -2.23M | -3.14M | -1.80M | -2.95M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Investing | -- | -- | -- | -- | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 4.04M | -- | -- | 15.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | -327.00K | -967.00K |
| Cash from Financing | 0.00 | 4.04M | 0.00 | -327.00K | 14.03M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.70M | 1.81M | -3.14M | -2.13M | 11.08M |